IQ-AI Limited’s (LON:IQAI) subsidiary, Imaging Biometrics (IB) recently signed a global distribution deal for imaging analysis software designed to detect chronic liver disease (CLD) and CEO Mike Schmainda tells Proactive why that's been so significant.
Under the agreement with US firm AI Metrics, IB will receive non-exclusive global rights to market and distribute the product, known as LSN. News here too on the brain tumour analysis platform and what other products are in the pipeline.
15 Jan 20